FT
FireCyte is a neuroscience-based ophthalmology company developing novel multi-target intravitreal injected proteins for retinal disorders. These fusion proteins engage SORT1 and DCC to modulate microglial behavior, offering both anti-inflammatory and neuroprotective effects. The company's approach focuses on direct protection of neurons through targeted neuroscience research.
Updated 3 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- FireCyte is a neuroscience-based ophthalmology company developing novel multi-target intravitreal injected proteins for retinal disorders. These fusion proteins engage SORT1 and DCC to modulate microglial behavior, offering both anti-inflammatory and neuroprotective effects. The company's approach focuses on direct protection of neurons through targeted neuroscience research.